Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis.

cryopreservation fertility preservation menopause oncofertility ovarian tissue premature ovarian insufficiency transplantation

Journal

Human reproduction update
ISSN: 1460-2369
Titre abrégé: Hum Reprod Update
Pays: England
ID NLM: 9507614

Informations de publication

Date de publication:
02 05 2022
Historique:
received: 29 06 2020
revised: 29 12 2021
pubmed: 25 2 2022
medline: 10 5 2022
entrez: 24 2 2022
Statut: ppublish

Résumé

Ovarian tissue cryopreservation involves freezing and storing of surgically retrieved ovarian tissue in liquid or vapour nitrogen below -190°C. The tissue can be thawed and transplanted back with the aim of restoring fertility or ovarian endocrine function. The techniques for human ovarian tissue freezing and transplantation have evolved over the last 20 years, particularly in the context of fertility preservation in pre-pubertal cancer patients. Fresh ovarian tissue transplantation, using an autograft or donor tissue, is a more recent development; it has the potential to preserve fertility and hormonal function in women who have their ovaries removed for benign gynaecological conditions. The techniques of ovarian tissue cryopreservation and transplantation have progressed rapidly since inception; however, the evidence on the success of this intervention is largely based on case reports and case series. The aim of this study was to systematically review the current evidence by incorporating study-level and individual patient-level meta-analyses of women who received ovarian transplants, including frozen-thawed transplant, fresh or donor graft. The review protocol was registered with PROSPERO (CRD42018115233). A comprehensive literature search was performed using MEDLINE, EMBASE, CINAHL and Cochrane Central Register of Controlled Trials from database inception to October 2020. Authors were also contacted for individual patient data if relevant outcomes were not reported in the published manuscripts. Meta-analysis was performed using inverse-variance weighting to calculate summary estimates using a fixed-effects model. The review included 87 studies (735 women). Twenty studies reported on ≥5 cases of ovarian transplants and were included in the meta-analysis (568 women). Fertility outcomes included pregnancy, live birth and miscarriage rates, and endocrine outcomes included oestrogen, FSH and LH levels. The pooled rates were 37% (95% CI: 32-43%) for pregnancy, 28% (95% CI: 24-34%) for live birth and 37% (95% CI: 30-46%) for miscarriage following frozen ovarian tissue transplantation. Pooled mean for pre-transplant oestrogen was 101.6 pmol/l (95% CI: 47.9-155.3), which increased post-transplant to 522.4 pmol/l (95% CI: 315.4-729; mean difference: 228.24; 95% CI: 180.5-276). Pooled mean of pre-transplant FSH was 66.4 IU/l (95% CI: 52.8-84), which decreased post-transplant to 14.1 IU/l (95% CI: 10.9-17.3; mean difference 61.8; 95% CI: 57-66.6). The median time to return of FSH to a value <25 IU/l was 19 weeks (interquartile range: 15-26 weeks; range: 0.4-208 weeks). The median duration of graft function was 2.5 years (interquartile range: 1.4-3.4 years; range: 0.7-5 years). The analysis demonstrated that ovarian tissue cryopreservation and transplantation could restore reproductive and hormonal functions in women. Further studies with larger samples of well-characterized populations are required to define the optimal retrieval, cryopreservation and transplantation processes. Ovarian tissue cryopreservation and transplantation may not only be effective in restoring fertility but also the return of reproductive endocrine function. Although this technology was developed as a fertility preservation option, it may have the scope to be considered for endocrine function preservation.

Sections du résumé

BACKGROUND
Ovarian tissue cryopreservation involves freezing and storing of surgically retrieved ovarian tissue in liquid or vapour nitrogen below -190°C. The tissue can be thawed and transplanted back with the aim of restoring fertility or ovarian endocrine function. The techniques for human ovarian tissue freezing and transplantation have evolved over the last 20 years, particularly in the context of fertility preservation in pre-pubertal cancer patients. Fresh ovarian tissue transplantation, using an autograft or donor tissue, is a more recent development; it has the potential to preserve fertility and hormonal function in women who have their ovaries removed for benign gynaecological conditions. The techniques of ovarian tissue cryopreservation and transplantation have progressed rapidly since inception; however, the evidence on the success of this intervention is largely based on case reports and case series.
OBJECTIVE AND RATIONALE
The aim of this study was to systematically review the current evidence by incorporating study-level and individual patient-level meta-analyses of women who received ovarian transplants, including frozen-thawed transplant, fresh or donor graft.
SEARCH METHODS
The review protocol was registered with PROSPERO (CRD42018115233). A comprehensive literature search was performed using MEDLINE, EMBASE, CINAHL and Cochrane Central Register of Controlled Trials from database inception to October 2020. Authors were also contacted for individual patient data if relevant outcomes were not reported in the published manuscripts. Meta-analysis was performed using inverse-variance weighting to calculate summary estimates using a fixed-effects model.
OUTCOMES
The review included 87 studies (735 women). Twenty studies reported on ≥5 cases of ovarian transplants and were included in the meta-analysis (568 women). Fertility outcomes included pregnancy, live birth and miscarriage rates, and endocrine outcomes included oestrogen, FSH and LH levels. The pooled rates were 37% (95% CI: 32-43%) for pregnancy, 28% (95% CI: 24-34%) for live birth and 37% (95% CI: 30-46%) for miscarriage following frozen ovarian tissue transplantation. Pooled mean for pre-transplant oestrogen was 101.6 pmol/l (95% CI: 47.9-155.3), which increased post-transplant to 522.4 pmol/l (95% CI: 315.4-729; mean difference: 228.24; 95% CI: 180.5-276). Pooled mean of pre-transplant FSH was 66.4 IU/l (95% CI: 52.8-84), which decreased post-transplant to 14.1 IU/l (95% CI: 10.9-17.3; mean difference 61.8; 95% CI: 57-66.6). The median time to return of FSH to a value <25 IU/l was 19 weeks (interquartile range: 15-26 weeks; range: 0.4-208 weeks). The median duration of graft function was 2.5 years (interquartile range: 1.4-3.4 years; range: 0.7-5 years). The analysis demonstrated that ovarian tissue cryopreservation and transplantation could restore reproductive and hormonal functions in women. Further studies with larger samples of well-characterized populations are required to define the optimal retrieval, cryopreservation and transplantation processes.
WIDER IMPLICATIONS
Ovarian tissue cryopreservation and transplantation may not only be effective in restoring fertility but also the return of reproductive endocrine function. Although this technology was developed as a fertility preservation option, it may have the scope to be considered for endocrine function preservation.

Identifiants

pubmed: 35199164
pii: 6535334
doi: 10.1093/humupd/dmac003
pmc: PMC9733829
doi:

Substances chimiques

Estrogens 0
Follicle Stimulating Hormone 9002-68-0

Types de publication

Journal Article Meta-Analysis Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

400-416

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

Geburtshilfe Frauenheilkd. 2021 Mar;81(3):331-338
pubmed: 33692594
J Pediatr Adolesc Gynecol. 2010 Apr;23(2):107-10
pubmed: 19896400
Hum Reprod. 2021 Aug 18;36(9):2473-2483
pubmed: 34255039
Lancet Oncol. 2016 Jun;17(6):e240-e253
pubmed: 27299280
Ann Clin Biochem. 2009 Nov;46(Pt 6):441-56
pubmed: 19841104
Maturitas. 1996 Apr;23(3):319-26
pubmed: 8794427
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Assist Reprod Genet. 2020 Apr;37(4):891-904
pubmed: 32096110
N Engl J Med. 2005 Jul 7;353(1):58-63
pubmed: 15941849
Fertil Steril. 2004 Oct;82(4):954-6
pubmed: 15482779
Crit Rev Oncol Hematol. 2020 Oct;154:103092
pubmed: 32896752
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Fertil Steril. 2011 Feb;95(2):804.e7-10
pubmed: 20801441
Fertil Steril. 2005 Oct;84(4):1018
pubmed: 16213862
N Engl J Med. 2005 Jul 21;353(3):318-21
pubmed: 15983020
Fertil Steril. 2018 Mar;109(3):478-485.e2
pubmed: 29428307
Acta Obstet Gynecol Scand. 2015 Mar;94(3):324-8
pubmed: 25545009
Lancet. 2004 Oct 16-22;364(9443):1405-10
pubmed: 15488215
Hum Reprod. 2016 May;31(5):926-37
pubmed: 27008889
J Clin Endocrinol Metab. 2011 Apr;96(4):1136-44
pubmed: 21289248
Acta Obstet Gynecol Scand. 2005 Jul;84(7):695-8
pubmed: 15954881
Stat Med. 1987 Apr-May;6(3):341-50
pubmed: 3616287
Hum Reprod. 2014 Sep;29(9):1931-40
pubmed: 24958067
BMC Med. 2016 Jan 04;14:1
pubmed: 26728489
Gynecol Surg. 2017;14(1):9
pubmed: 28725171
Gynecol Endocrinol. 2019 Dec;35(12):1043-1049
pubmed: 31373236
J Assist Reprod Genet. 2018 Dec;35(12):2205-2213
pubmed: 30255455
Reprod Biomed Online. 2018 Sep;37(3):359-366
pubmed: 30314888
JBRA Assist Reprod. 2015 Feb 01;19(1):29-32
pubmed: 27205864
Obstet Gynecol. 2017 Jun;129(6):1035-1036
pubmed: 28486360
Fertil Steril. 2020 Aug;114(2):379-387
pubmed: 32624219
Pediatr Transplant. 2006 Nov;10(7):782-7
pubmed: 17032423
Support Care Cancer. 2002 Nov;10(8):579-600
pubmed: 12436217
Hum Reprod. 2014 Apr;29(4):835-41
pubmed: 24549218
Fertil Steril. 2011 Dec;96(6):1407-11
pubmed: 21982291
Lancet. 2001 Apr 14;357(9263):1172-5
pubmed: 11323045
Hum Reprod. 2018 Jul 1;33(7):1281-1290
pubmed: 29912328
Hum Reprod. 2016 Aug;31(8):1827-37
pubmed: 27312534
J Assist Reprod Genet. 2020 Apr;37(4):987-1015
pubmed: 32236903
Reprod Biomed Online. 2012 Aug;25(2):128-32
pubmed: 22687323
Fertil Steril. 2010 Nov;94(6):2330.e11-2
pubmed: 20447628
Reprod Biomed Online. 2004 Apr;8(4):448-53
pubmed: 15149569
Hum Reprod. 2019 Jun 4;34(6):1083-1094
pubmed: 31116405
Hum Reprod. 2015 Dec;30(12):2838-45
pubmed: 26443605
Hum Reprod. 2008 Jul;23(7):1531-7
pubmed: 18285322
Minerva Ginecol. 2018 Aug;70(4):432-435
pubmed: 29696941
Reprod Biomed Online. 2015 Jun;30(6):643-50
pubmed: 25892498
J Clin Endocrinol Metab. 2001 Sep;86(9):4489-94
pubmed: 11549698
Fertil Steril. 2003 Jul;80(1):193-8
pubmed: 12849823
Acta Obstet Gynecol Scand. 2015 Sep;94(9):937-41
pubmed: 26095872
Acta Obstet Gynecol Scand. 2020 Feb;99(2):213-221
pubmed: 31538662
Fertil Steril. 2013 Jan;99(1):227-230
pubmed: 23102860
Reproduction. 2019 Nov;158(5):F27-F34
pubmed: 31284266
Mol Hum Reprod. 2012 Feb;18(2):59-67
pubmed: 22205727
Hum Fertil (Camb). 2018 Apr;21(1):3-26
pubmed: 29298394
Hum Reprod. 2011 May;26(5):1097-103
pubmed: 21421665
Fertil Steril. 2015 Nov;104(5):1097-8
pubmed: 26342246
BMC Womens Health. 2019 May 14;19(1):65
pubmed: 31088441
J Assist Reprod Genet. 2015 Aug;32(8):1167-70
pubmed: 26210678
Fertil Steril. 2019 Dec;112(6):1022-1033
pubmed: 31843073
Reprod Biomed Online. 2016 Mar;32(3):334-6
pubmed: 26776823
BMJ. 2017 Apr 5;357:j1390
pubmed: 28381561
Fertil Steril. 2010 Nov;94(6):2191-6
pubmed: 20171622
Nat Rev Endocrinol. 2013 Dec;9(12):735-49
pubmed: 24166000
J Clin Endocrinol Metab. 2016 Nov;101(11):4405-4412
pubmed: 27571179
Hum Reprod. 2010 Oct;25(10):2489-95
pubmed: 20663793
Hum Reprod. 2015 Mar;30(3):608-15
pubmed: 25567618
N Engl J Med. 2017 Oct 26;377(17):1657-1665
pubmed: 29069558
J Korean Med Sci. 2018 Apr 30;33(21):e156
pubmed: 29780295
Hum Reprod. 2014 Aug;29(8):1828
pubmed: 24871346
Hum Reprod. 2009 Nov;24(11):2778-87
pubmed: 19671623
Hum Reprod. 2006 Jan;21(1):183-8
pubmed: 16126712
Hum Reprod. 2016 Sep;31(9):2031-41
pubmed: 27378768
Acta Obstet Gynecol Scand. 2019 May;98(5):630-637
pubmed: 30919447
J Assist Reprod Genet. 2013 Mar;30(3):305-14
pubmed: 23417329
Arch Gynecol Obstet. 2018 Jan;297(1):257-267
pubmed: 29181578
J Transl Med. 2019 Nov 29;17(1):396
pubmed: 31783875
Clin Med Insights Reprod Health. 2019 Aug 06;13:1179558119867357
pubmed: 31431803
Ann Med. 2011;43(6):437-50
pubmed: 21226660
Ginekol Pol. 2016;87(3):235-40
pubmed: 27306136
BMC Med Res Methodol. 2020 May 12;20(1):113
pubmed: 32398016
Fertil Steril. 2005 Nov;84(5):1509
pubmed: 16275256
Cancer. 2004 Dec 15;101(12):2771-8
pubmed: 15534884
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Support Care Cancer. 2001 Oct;9(7):489-513
pubmed: 11680830
J Ovarian Res. 2013 May 07;6(1):33
pubmed: 23647552
Hum Reprod. 2007 Mar;22(3):786-91
pubmed: 17110398
Fertil Steril. 2011 Apr;95(5):1787.e1-4
pubmed: 21145049
Fertil Steril. 2020 Aug;114(2):388-397
pubmed: 32605799
Fertil Steril. 2018 Jan;109(1):48-53
pubmed: 29198847
Reprod Biomed Online. 2011 Feb;22(2):162-71
pubmed: 21239230
Fertil Steril. 2010 Feb;93(3):762-8
pubmed: 19013568
Sci Rep. 2017 Aug 17;7(1):8538
pubmed: 28819292
Fertil Steril. 2012 Jun;97(6):1260-8
pubmed: 22656306
Hum Reprod. 2007 Oct;22(10):2653-9
pubmed: 17670763
Hum Reprod Open. 2020 Nov 14;2020(4):hoaa052
pubmed: 33225079
Reprod Biomed Online. 2018 Feb;36(2):188-196
pubmed: 29198423
J Assist Reprod Genet. 2018 Apr;35(4):561-570
pubmed: 29497953
J Assist Reprod Genet. 2019 Sep;36(9):1805-1822
pubmed: 31399917
Fertil Steril. 2017 May;107(5):1206-1213
pubmed: 28433369
Biomed Res Int. 2014;2014:482968
pubmed: 25165706
Climacteric. 2017 Dec;20(6):540-544
pubmed: 28933974
Fertil Steril. 2015 Feb;103(2):462-8
pubmed: 25487750
Cancer Treat Res. 2007;138:201-17
pubmed: 18080667
Am J Obstet Gynecol. 2016 Jan;214(1):94.e1-9
pubmed: 26601616
Fertil Steril. 2016 Aug;106(2):467-74
pubmed: 27181924
Maturitas. 2012 Jul;72(3):249-55
pubmed: 22572589
Taiwan J Obstet Gynecol. 2009 Mar;48(1):69-71
pubmed: 19346196
Arch Gynecol Obstet. 2017 Apr;295(4):1033-1039
pubmed: 28197717
Fertil Steril. 2021 May;115(5):1102-1115
pubmed: 33933173

Auteurs

Hajra Khattak (H)

Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Rosamund Malhas (R)

Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Laurentiu Craciunas (L)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Yousri Afifi (Y)

Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Christiani A Amorim (CA)

Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.

Simon Fishel (S)

CARE Fertility Group, Nottingham, UK.
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.

Sherman Silber (S)

Infertility Centre of St. Louis, Saint Louis, MO, USA.

Debra Gook (D)

Reproductive Services/Melbourne IVF, The Royal Women's Hospital, Parkville, VIC, Australia.

Isabelle Demeestere (I)

Research Laboratory on Human Reproduction, Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Olga Bystrova (O)

AVA-PETER Fertility Clinic, Saint-Petersburg, Russia.

Alla Lisyanskaya (A)

Division of Gynecologic Oncology, Saint-Petersburg City Oncology Clinic, Saint-Petersburg, Russia.

Georgy Manikhas (G)

Department of Oncology of the First Pavlov State Medical University of Saint-Petersburg, Saint-Petersburg, Russia.

Laura Lotz (L)

Department of Obstetrics and Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.

Ralf Dittrich (R)

Department of Obstetrics and Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.

Lotte Berdiin Colmorn (LB)

The Fertility Clinic, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.

Kirsten Tryde Macklon (KT)

The Fertility Clinic, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.

Ina Marie Dueholm Hjorth (IMD)

Department of Obstetrics and Gynaecology, Aarhus University Hospital, Aarhus, Denmark.

Stine Gry Kristensen (SG)

Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children and Reproduction, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.

Ioannis Gallos (I)

Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Arri Coomarasamy (A)

Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH